Jinbo Yue, Doctor
Shandong Cancer Hospital and Institute
Emerging Leaders
#552 pts
Current Leaders
#12926 pts
All-Time Leaders
#7652 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2023. 8 trials as lead/chair. How it works →
Trials led — by scientific impact
Continuation of First-line Therapy With Radiotherapy for Oligoprogression Versus Early Switch to Second-line Therapy in Oligoprogressive Hepatocellular Carcinoma (CROSS): a Multi-center, Randomized, Controlled, Open-label, Phase Ⅲ Trial
Phase 3RecruitingShandong Cancer Hospital and Institute
10
impact
A Phase II Randomized Controlled Clinical Study on the Efficacy and Safety Evaluation of Radiotherapy Mode Based on SFRT and SCART Technologies for Bone Metastatic Malignant Tumors With Soft Tissue Formation
N/ARecruitingShandong Cancer Hospital and Institute
10
impact
Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study
Phase 1SuspendedShandong Cancer Hospital and Institute
8
impact
Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer: A Prospective Clinical Trial
Phase 2ActiveShandong Cancer Hospital and Institute
7
impact
Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma:A Multicenter，Prospective, Phase II, Randomized Controlled Trial
N/ARecruitingShandong Cancer Hospital and Institute
7
impact
Efficacy and Safety of Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled, Phase III Trial
N/ASuspendedShandong Cancer Hospital and Institute
5
impact
Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) -A Single-Arm Phase Ib/II Trial
Phase 2RecruitingShandong Cancer Hospital and Institute
5
impact
Bevacizumab Plus Iparomlimab/Tuvonralimab With Hepatic Artery Infusion Chemotherapy Followed by Stereotactic Body Radiotherapy in Patients With BCLC Stage C Hepatocellular Carcinoma With Thrombus and/or Extrahepatic Oligometastases (BITS-TO-HCC): Study Protocol of a Prospective, Single- Center, Single-Arm, Phase II Study
Phase 2RecruitingShandong Cancer Hospital and Institute
0
impact